Elicio Therapeutics, Inc. (ELTX)
| Market Cap | 133.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -51.28M |
| Shares Out | 15.98M |
| EPS (ttm) | -3.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,104 |
| Open | 8.39 |
| Previous Close | 8.29 |
| Day's Range | 8.14 - 8.40 |
| 52-Week Range | 3.70 - 9.99 |
| Beta | 2.11 |
| Analysts | Strong Buy |
| Price Target | 9.50 (+13.57%) |
| Earnings Date | Aug 12, 2025 |
About ELTX
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ELTX stock is "Strong Buy." The 12-month stock price target is $9.5, which is an increase of 13.57% from the latest price.
News
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
BOSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for...
Elicio Therapeutics Secures $10 Million in Financing
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025.
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunother...
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunother...
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data
Interim analysis from the phase 1/2 AMPLIFY-7P study, using ELI-002 for the treatment of KRAS mutant pancreatic cancer patients, is expected in the 1st half of 2025. The global pancreatic cancer marke...
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
Updated Phase 1 data include a 16.3-month median recurrence-free survival (“mRFS”) and 28.9-month median overall survival (“mOS”) from full study population
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025 Poster presentation at the Society for I...
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit to highlight data from AMPLIFY-7P and AMPLIFY-201 Phase 1 stu...
Elicio Therapeutics Reports Inducement Grants
BOSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunothera...
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunother...
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunothera...
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
• AMPLIFY-7P Phase 1 preliminary disease-free (“DFS”) survival demonstrates strong correlation between T cell response and reduced risk of progression or death• AMPLIFY-7P Phase 1 data presented at A...
Elicio Therapeutics Announces Proposed Public Offering
BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunothera...
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma ELI-002 7P administered as a monotherapy at th...
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherap...
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherap...
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunother...
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunother...
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
BOSTON, March 29, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunothera...
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunother...
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunother...